India’s drug regulator has given approval for a study to be conducted by the Christian Medical College (CMC), Vellore on mixing of COVID-19 vaccines Covaxin and Covishield, official sources said on Wednesday. An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on July 29 had recommended granting permission for conducting the study.
The trial will involve 300 healthy volunteers. “The aim of the study is to assess the feasibility on whether a person can be given two different vaccine shots — one each of Covishield and Covaxin — to complete the inoculation course,” a source said.
Separately, a recent study by the Indian Council of Medical Research (ICMR) involving 98 people, 18 of whom had inadvertently received Covishield as the first dose and Covaxin as the second in Uttar Pradesh, showed that combining these two COVID-19 vaccines elicited better immunogenicity than two doses of the same vaccine. The study also found that immunisation with combination of Covishield and Covaxin was safe and the adverse effects were also found to be similar when compared to the same dose regimen.
- Molbio’s Nipah test kit gets DCGI approval - September 9, 2021
- 61 test negative for Nipah so far: Kerala Health Minister Veena George - September 9, 2021
- RT-PCR accounted for over 70 percent tests conducted in Delhi in last five months - September 9, 2021
- Punjab govt to open 300 new Opioid Assisted Treatment centres to tackle drug addiction - September 9, 2021
- Over five crore people vaccinated in Madhya Pradesh so far - September 9, 2021
- BMC issues new Ganpati festival norms – No pandal darshan, curbs on yatra participants across Mumbai - September 8, 2021
- Early screening & risk assessment through breakthrough technologies - September 8, 2021
- 30 test negative for Nipah so far: Kerala Health Minister Veena George - September 8, 2021
- 88 oxygen generation plants functional in MP, says CM Shivraj Singh Chouhan - September 8, 2021
- Efforts grow to stamp out use of parasite drug for COVID-19 - September 8, 2021